Aquestive Therapeutics (AQST) Scheduled to Post Earnings on Wednesday

Share on StockTwits

Aquestive Therapeutics (NASDAQ:AQST) will post its quarterly earnings results before the market opens on Wednesday, August 7th. Analysts expect Aquestive Therapeutics to post earnings of ($0.67) per share for the quarter. Aquestive Therapeutics has set its FY 2019 guidance at EPS.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.10). The firm had revenue of $12.64 million during the quarter, compared to analyst estimates of $10.66 million. On average, analysts expect Aquestive Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

NASDAQ AQST opened at $3.13 on Tuesday. The company has a market cap of $82.67 million and a P/E ratio of -1.12. The company has a current ratio of 1.89, a quick ratio of 1.71 and a debt-to-equity ratio of 4.23. The firm’s 50 day moving average is $4.12. Aquestive Therapeutics has a fifty-two week low of $2.96 and a fifty-two week high of $20.70.

Several equities analysts have recently weighed in on the company. Zacks Investment Research downgraded Aquestive Therapeutics from a “buy” rating to a “sell” rating in a research report on Monday, May 20th. Wedbush set a $31.00 target price on Aquestive Therapeutics and gave the company a “buy” rating in a research report on Friday, July 5th. HC Wainwright assumed coverage on Aquestive Therapeutics in a research report on Monday, April 22nd. They set a “buy” rating and a $10.00 target price on the stock. Finally, ValuEngine raised Aquestive Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $19.54.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.

See Also: Rule of 72

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Jennison Associates LLC Sells 760,927 Shares of Amicus Therapeutics, Inc.
Jennison Associates LLC Sells 760,927 Shares of Amicus Therapeutics, Inc.
Jennison Associates LLC Sells 102,429 Shares of EOG Resources Inc
Jennison Associates LLC Sells 102,429 Shares of EOG Resources Inc
Jennison Associates LLC Increases Stock Holdings in BB&T Co.
Jennison Associates LLC Increases Stock Holdings in BB&T Co.
Jennison Associates LLC Sells 67,785 Shares of Performance Food Group Co
Jennison Associates LLC Sells 67,785 Shares of Performance Food Group Co
Jennison Associates LLC Boosts Stock Position in MFA FINL INC/SH
Jennison Associates LLC Boosts Stock Position in MFA FINL INC/SH
Jennison Associates LLC Lowers Stock Holdings in Mcdonald’s Corp
Jennison Associates LLC Lowers Stock Holdings in Mcdonald’s Corp


© 2006-2019 Ticker Report